一分钟看懂
这是一项关于腺癌的II 期 / III 期研究，登记的药物或干预包括Biospecimen Collection；Computed Tomography；Magnetic Resonance Imaging；Nivolumab；Paclitaxel；Questionnaire Administration；Ramucirumab，当前状态为招募中。登记地点显示中国Little Rock、Anaheim、Baldwin Park、Bellflower等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Biospecimen Collection；Computed Tomography；Magnetic Resonance Imaging；Nivolumab；Paclitaxel；Questionnaire Administration；Ramucirumab · II 期 / III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记摘要未单独列出可展示的排除条件，请查看英文原文并向研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Baptist Health Medical Center - Little Rock · Little Rock
- University of Arkansas for Medical Sciences · Little Rock
- Kaiser Permanente-Anaheim · Anaheim
- Kaiser Permanente-Baldwin Park · Baldwin Park
- Kaiser Permanente-Bellflower · Bellflower
- Tower Cancer Research Foundation · Beverly Hills
- Kaiser Permanente Dublin · Dublin
- Kaiser Permanente-Fontana · Fontana
- Kaiser Permanente-Fremont · Fremont
- Kaiser Permanente Fresno Orchard Plaza · Fresno
- Kaiser Permanente-Fresno · Fresno
- Kaiser Permanente South Bay · Harbor City
- Kaiser Permanente-Irvine · Irvine
- UC San Diego Moores Cancer Center · La Jolla
- Keck Medicine of USC Koreatown · Los Angeles
- Kaiser Permanente Los Angeles Medical Center · Los Angeles
- Los Angeles General Medical Center · Los Angeles
- USC / Norris Comprehensive Cancer Center · Los Angeles
- Kaiser Permanente West Los Angeles · Los Angeles
- Cedars-Sinai Medical Center · Los Angeles
- Kaiser Permanente- Modesto MOB II · Modesto
- Kaiser Permanente-Modesto · Modesto
- USC Norris Oncology/Hematology-Newport Beach · Newport Beach
- Kaiser Permanente-Oakland · Oakland
- Kaiser Permanente-Ontario · Ontario
- Kaiser Permanente - Panorama City · Panorama City
- Kaiser Permanente-Riverside · Riverside
- Kaiser Permanente-Roseville · Roseville
- Kaiser Permanente Downtown Commons · Sacramento
- University of California Davis Comprehensive Cancer Center · Sacramento
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Participants must have advanced or locally unresectable gastric, gastroesophageal junction or esophageal adenocarcinoma
- * Participants must have PD-L1 CPS (Combined Positive Score) ≥ 1. This test would have been performed as part of standard of care (SOC) pathology testing, using tissue obtained within two years prior to registration and collected prior to or after a frontline regimen
- * Participants must have a histologically confirmed diagnosis of microsatellite stable (MSS) and HER2 negative gastric, gastroesophageal junction, or esophageal adenocarcinoma
- * Participants must have documented unresectable and/or metastatic disease on CT or MRI imaging completed prior to registration. Imaging must have been completed within 28 days prior to registration for participants with measurable disease. CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form
- * Participants with treated brain metastases must have no evidence of progression on the follow-up brain imaging after central nervous system (CNS)-directed therapy. All treatment for brain metastases must have been completed at least 28 days prior to registration
- * Participants must have disease progression or intolerance to frontline standard of care (SOC) chemotherapy plus either nivolumab, pembrolizumab or any other PD-1 or PD-L1 inhibitor. Peri-operative chemotherapy plus nivolumab, pembrolizumab or any other PD-1 or PD-L1 inhibitor will count as one line if disease progression occurs while on the therapy or within 6 months of completing the chemotherapy plus nivolumab or pembrolizumab or other PD-1/PD-L1 inhibitor cycle
- * Participants must not have received more than one prior line of systemic therapy defined as chemotherapy plus either nivolumab, pembrolizumab, or any other PD-1 or PD-L1 inhibitor, in the stage IV or unresectable setting. Peri-operative or adjuvant nivoluamb or other PD-1/PD-L1 inhibitors would count as one prior line of systemic therapy if patients progressed while on nivolumab (or other PD-1/PD-L1 inhibitors) or within 6 months of stopping it
- Note: Radiation or any other regional therapy options done to address local residual disease or metastatic disease would not count as a line of therapy. Maintenance therapy with a different form of fluoropyrimidine (i.e. switching from capecitabine to fluorouracil \[5FU\]) would not count as another line of therapy
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06203600；登记信息更新于 2026-10-07；本站同步于 2026-10-08。